iConquerMS, a research community of people with MS supported by the nonprofit organization Accelerated Cure Project for MS is conducting a research study to learn about the COVID-19 vaccines in people with MS. The data will be analyzed on an ongoing basis.
To participate, you’ll need to create an account at iConquerMS.org and enroll in the iConquerMS Covid-19 Vaccination Study (COVER-MS). For more information, please visit:
I posted this under someone else's post the other day.. And yes! this is an awesome project they are doing. They have started looking at reactions to the vaccine for COVID now too as well as if any of us who have MS has had the disease and how we have recovered from it...
Post the results (or location) here when they are available. Thanks! I've read that there are no adverse effects with a MS diagnosis but some of the DMTs may reduce ones immune response which may cause trouble.
At my recent neurologist appointment, I was asked to be part of a trial for Moderna/Techfidera doing antibody tests over an 18 month period following vaccination. Is this a similar study?
Thanks for sharing NJ-girl . This looks to be a different study than the one you mentioned above and is not a trial for an MS treatment; it is called the iConquerMS COVID-19 Vaccination Study (COVER-MS).
If you are still unsure about this study, please feel free to contact iConquerMS directly at info@iConquerMS.org.
If you go to their homepage, you will see a link under "See what we're learning" in a mention of their COVID-19 vaccines in people with MS study, which links to a PDF of recent results. Other published study results will be revealed by iConquerMS on their website as well
Thank you again to everyone who participated so far to help iConquerMS in their study!
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.